Is there a risk of disease rebound after stopping eculizumab?

Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... See full prescribing information for. SOLIRIS. SOLIRIS® (eculizumab) injection, for intravenous use. Initial U.S. Approval: 2007. WARNING: SERIOUS MENINGOCOCCAL ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. Mar 30, 2022 ... What Are Warnings and Precautions for Eculizumab? · Discontinue if being treated for serious meningococcal infection · Supplement dose with ... May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. In this way Soliris improves anaemia, tiredness, and other signs and symptoms of PNH. Patients with aHUS have an inflammatory condition which affects the blood ... Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ...